Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Home (current)
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    CONy 2023
    ACTRIMS 2023
    ISC 2023
    EHC 2022
    AES 2022
    WSC 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Dalia Rotstein

Predictors of early serologic diagnosis of AQ4-IgG positive NMOSD 2:18
Predictors of early serologic diagnosis of AQ4-IgG positive NMOSD
Dalia Rotstein • 27 Oct 2022
When to make a timely switch to high-efficacy DMT for MS 0:47
When to make a timely switch to high-efficacy DMT for MS
Dalia Rotstein • 27 Oct 2022
Proportion of life and incidence of MS in Canadian immigrants 1:40
Proportion of life and incidence of MS in Canadian immigrants
Dalia Rotstein • 27 Oct 2022
When to consider an escalation approach for MS treatment 2:12
When to consider an escalation approach for MS treatment
Dalia Rotstein • 27 Oct 2022
Chronic cognitive impairment improved after eculizumab initiation in cases of NMOSD 2:50
Chronic cognitive impairment improved after eculizumab initiation in cases of NMOSD
Dalia Rotstein • 25 Feb 2022
Is EBV the main cause of MS onset? 2:28
Is EBV the main cause of MS onset?
Dalia Rotstein • 25 Feb 2022
Prognostic factors in NMOSD: age, ethnicity, and relapse history 2:07
Prognostic factors in NMOSD: age, ethnicity, and relapse history
Dalia Rotstein • 8 Oct 2021
Key research questions in seronegative NMOSD 1:30
Key research questions in seronegative NMOSD
Dalia Rotstein • 8 Oct 2021
Identifying risk factors for AQP4+ NMOSD 3:18
Identifying risk factors for AQP4+ NMOSD
Dalia Rotstein • 8 Oct 2021
The predictive value of NEDA-3 for long-term disability in MS 4:03
The predictive value of NEDA-3 for long-term disability in MS
Dalia Rotstein • 8 Oct 2021
Improving educational opportunities for neurology residents globally 1:17
Improving educational opportunities for neurology residents globally
Dalia Rotstein • 16 Feb 2021
The impact of social networks on physical impairment in MS 1:34
The impact of social networks on physical impairment in MS
Dalia Rotstein • 16 Feb 2021
No evidence of disease activity as a predictive measure of long-term disability in RRMS 2:51
No evidence of disease activity as a predictive measure of long-term disability in RRMS
Dalia Rotstein • 16 Feb 2021
What to look out for at ACTRIMS 2021 2:17
What to look out for at ACTRIMS 2021
Dalia Rotstein • 16 Feb 2021
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy